Stock BWVI BLUE WATER VENTURES INTERNATIONAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Blue Water Ventures International, Inc.

Equities

BWVI

US09609E1055

Market Closed - OTC Markets
Other stock markets
 15:54:29 2024-05-24 EDT 		5-day change 1st Jan Change
0.0022 USD 0.00% Intraday chart for Blue Water Ventures International, Inc. -93.71% -96.45%
2023 Psycheceutical Bioscience, Inc. Announces Chief Executive Officer Changes CI
2023 Psycheceutical Bioscience, Inc. Appoints Neilank K. Jha as Its New Executive Chairman CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Psycheceutical Bioscience, Inc. Announces Chief Executive Officer Changes
CI
Psycheceutical Bioscience, Inc. Appoints Neilank K. Jha as Its New Executive Chairman
CI
Blue Water Ventures International, Inc. announced that it expects to receive $5 million in funding
CI
Psycheceutical Bioscience, Inc Announces First Patient Has Been Dosed in Its Phase I Study to Evaluate Its Patented Neurodirectâ„¢ Ketamine Topical Delivery System for the Treatment of Post Traumatic Stress Disorder
CI
Veru Sells ENTADFI Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones
AQ
Psycheceutical Bioscience, Inc. Named a 2023 Top 10 Biotech Startup by Life Sciences Review
PR
Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab
GL
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD
GL
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD
AQ
Psycheceutical Bioscience, Inc. Announces Publication of Pre-Clinical Observational Data Supports Potential of its NeuroDirect™ Ketamine Topical Cream as Treatment for PTSD
CI
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
GL
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
AQ
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
CI
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD
GL
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD
AQ
Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD
GL
Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD
AQ
Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer
GL
Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer
AQ
Dr. Aric Logsdon Joins Psycheceutical Bioscience, Inc. as Company’s Scientific Director
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BWVI Stock
  4. News Blue Water Ventures International, Inc.